Cantor Fitzgerald reiterates an Overweight rating on Avita Medical (RCEL) following the company receiving FDA premarket approval for RECELL GO Mini, its miniaturized device designed to treat ...

Ellen DeGeneres and her wife, Ally McBeal and Arrested Development star Portia de Rossi, have reportedly opened up about the reason why they chose to move to the UK instead of Australia. The couple ...

Palvella Therapeutics (NASDAQ:PVLA – Free Report) – Research analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for Palvella Therapeutics in a research report ...

Brandon Lutnick, a trader at his father’s Cantor Fitzgerald LP, has been listed as CEO at its most recently created SPAC, Cantor Equity Partners I Inc., according to a filing Wednesday.

Brandon Lutnick, a trader at his father’s Cantor Fitzgerald LP, has been listed as CEO at its most recently created SPAC, Cantor Equity Partners I Inc., according to a filing Wednesday. The entity, ...

Trader Brandon Lutnick, 26, to run a new blank-check vehicle His father is giving up posts to join Trump’s administration Donald Trump’s commerce secretary nominee, Howard Lutnick, is taking a key ...

Cantor Fitzgerald CEO Howard Lutnick, the president-elect’s pick for commerce secretary, has purchased the Washington, D.C., home of Fox News anchor Bret Baier for $25 million.

Cantor Fitzgerald analyst Andres Sheppard reiterated a Buy rating on Archer Aviation (ACHR – Research Report) today and set a price target of $13.00. The company’s shares closed yesterday at ...

Cantor Fitzgerald raised its price target for the company Archer Aviation (ACHR, Financial) on Wednesday to $13.00 from $10.00, which pushed Archer stock soared 8% on Wednesday. This helped ...

With that in mind, Digital Foundry's Oliver Mackenzie spoke to PS5 Pro lead system architect Mark Cerny and core technology director at Insomniac Games, Mike Fitzgerald. This tech interview covers ...

On Tuesday, Cantor Fitzgerald initiated coverage on Esperion (NASDAQ:ESPR) Therapeutics, a biopharmaceutical company, with an Overweight rating and a price target of $8.00. The firm pointed out the ...